ClinicalTrials.gg
Enrolling by invitationNCT04451044DEFINE GPSUpdated Jan 20, 2025

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

An interventional study of Philips SyncVision system with Philips pressure wires and standard of care angiographically-guided PCI in Coronary Artery Disease and Ischemic Heart Disease, sponsored by Philips Clinical & Medical Affairs Global. Enrolling by invitation at 84 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Coronary Artery Disease by Philips — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Philips.

Started
2021
the only one that year
No phase
6 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Coronary Artery Disease by Philips, this one is the only one that started in 2021, is one of 6 with no phase, and was the 11th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 13 studies in Coronary Artery Disease by Philips is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Coronary Artery Disease by Philips, or all of them as a file.
02

Study summary

Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.

Read the detailed description

DEFINE GPS Substudy: Characterization of Intermediate Lesions (ChIL) will enroll approximately 350 patients at up to 20 sites. This multi-center, prospective, registry will enroll patients consented to be randomized into the DEFINE GPS study but ultimately screen fail. Baseline patient medical and demographic data will be collected along with angiographic and functional data from vessels with intermediate disease deferred from revascularization and will be used to establish a body of imaging data that can be used to validate new image-based physiology applications.

03

Conditions studied

  • Coronary Artery Disease
  • Ischemic Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Adult men and women (local age of consent) who present with stable or unstable angina, or NSTEMI.
    1. Undergoing cardiac catheterization with planned PCI or possible ad hoc PCI
    1. Following angiography, PCI is indicated in at least one coronary artery* on the basis of one or more of the following:

      1. Presenting with NSTE-ACS (unstable angina with changes or cardiac enzyme-positive NSTEMI) with an identified culprit lesion with DS ≥50%;
      2. One or more angiographic stenoses present with ≥80% stenosis severity by visual estimation;
      3. One or more angiographic stenoses present with ≥50% to \<80% stenosis severity by visual estimation and an abnormal non-invasive stress test in the distribution of the lesion(s) within the past 60 days;
      4. One or more angiographic stenoses are present with ≥50% to \<80% stenosis severity by visual estimation and a spot iFR measure ≤0.89 or FFR≤0.80 for borderline iFR..
  • 4 Subject is willing to comply with all scheduled visits and tests and has provided informed written consent

Exclusion criteria

Exclusion Criteria:

    1. STEMI within 30 days
    1. PCI within the prior 12 months, or any PCI planned after the study procedure (other than planned staged procedures of randomized vessels which are allowed)
    1. Prior CABG anytime
    1. Silent ischemia only (i.e. no cardiac symptoms related to coronary artery disease) within the prior 4 weeks
    1. Documented prior iFR pullback performed in any coronary artery including during the qualifying diagnostic angiogram
    1. Any vessel with in-stent restenosis (ISR) requiring treatment
    1. Cardiogenic shock defined as systolic blood pressure \<90 mmHg for >20 minutes not responding to fluid resuscitation, or need for inotropic, pressor, or device-based hemodynamic support
    1. Presence of unstable ventricular arrhythmias
    1. Heart rate > 110, including uncontrolled atrial fibrillation (AF)
    1. Decompensated congestive heart failure ( Class IV or Killip Class III or IV)
    1. Chronic total occlusion (CTO) of a target vessel (exception: a CTO may be present in a non-target vessel if it is supplying non-viable myocardium and there is no intent to open the CTO during the index or later procedure)
    1. Coronary anatomy not amenable to pressure wire manipulation due to extreme tortuosity or complexity such that it is unlikely that a pressure wire could be passed to the distal third of the three major epicardial coronary arteries
    1. Any angiographic giant thrombus (i.e., thrombus length > 3x RVD at lesion)
    1. Any target vessel with \< TIMI III flow
    1. Any target lesion with a reference vessel diameter (RVD) less than 2.25mm except for within the side branch of a bifurcation lesion
    1. Any non-target lesion with a reference vessel diameter (RVD) greater than 2.00mm that contains an ≥80% stenosis and is not intended for treatment with PCI (other than a CTO supplying non-viable myocardium - see exclusion #11)
    1. Known severe aortic or mitral valve stenosis/insufficiency
    1. Known non-cardiovascular comorbidity resulting in lifespan \<24 months
    1. Known ≤30%
    1. Estimated ( formula) \<30 mL/min/1.73m2 or on dialysis
    1. Any cardiac or non-cardiac surgical procedure planned within 12 months after enrollment, or any procedure planned within 6 months after enrollment that would necessitate discontinuation of dual antiplatelet therapy
    1. Known pregnancy or planning to become pregnant (women of must have a negative pregnancy test within 1 week of enrollment)
    1. Participating in another drug or device study that has not reached its primary endpoint
    1. Any condition such as dementia or substance abuse that may impair the patient's ability to comply with all study procedures, including medication compliance and follow-up visits
    1. Patient is a member of a vulnerable population who, in the judgment of the investigator, is unable to give for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also include university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
3,212 participants (estimated)

Study arms

  • Experimental
    physiologically-guided arm

    Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy

    Device: Philips SyncVision system with Philips pressure wires

  • Active comparator
    angiographically-guided arm

    Standard of care angiographically-guided PCI for determining the PCI strategy

    Procedure: standard of care angiographically-guided PCI

Interventions

  • DevicePhilips SyncVision system with Philips pressure wires

    Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy

  • Procedurestandard of care angiographically-guided PCI

    Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiac Events (MACE; composite of cardiac death, target vessel MI (TVMI), or ischemia-driven revascularization) or hospitalization for progressive or unstable angina at 2 years

    Time frame: 2 years

Secondary outcomes

  1. Major Adverse Cardiac Events (MACE; composite of cardiac death, target vessel MI (TVMI), or ischemia-driven revascularization) or hospitalization for progressive or unstable angina

    Time frame: 30 days, 1 year

  2. All-cause, cardiac and non-cardiac mortality

    Time frame: 30 days, 1 year and 2 years

  3. All MI, target vessel MI, non-target vessel MI, procedural MI, non-procedural MI

    Time frame: 30 days, 1 year and 2 years

  4. Ischemia-driven revascularization, including all revascularization, TVR, TLR, non-TLR TVR, and non-TVR

    Time frame: 30 days, 1 year and 2 years

  5. Hospitalization for progressive or unstable ischemia

    Time frame: 30 days, 1 year and 2 years

  6. Stent thrombosis (definite, probable and definite/probable)

    Time frame: 30 days, 1 year and 2 years

  7. Angina-related Quality of Life

    Change from baseline in the Seattle Angina Questionnaire (SAQ-7) summary score

    Time frame: 30 days, 1 year and 2 years

  8. Resource utilization

    The \[US-based\] cost of all health care resources associated with the index procedure and pre-specified event costs throughout the two-year follow up period

    Time frame: 30 days, 1 year and 2 years

  9. Cost effectiveness

    Cost per quality-adjusted life years gained

    Time frame: 30 days, 1 year and 2 years

07

Study locations

84 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2026, 60 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 60 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 30, 2020
StartActual
Jun 17, 2021
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2028
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451044
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jun 17, 2021
Primary completion
Jun 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jan 20, 2025

Study contacts

Allen Jeremias, MD MSC FACC FSCAI
principal investigator · Saint Francis Hospital
Gregg W Stone, MD
study chair · The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion